Human Recombinant CLK1, Active protein, GST Tag (V2LY-0526-LY3228)

Dekel, N., Eisenberg-Domovich, Y., Karlas, A., Meyer, T. F., Bracher, F., Lebendiker, M., ... & Livnah, O. (2020). Expression, purification and crystallization of CLK1 kinase–A potential target for antiviral therapy. Protein Expression and Purification, 176, 105742.

Babu, N., Pinto, S. M., Biswas, M., Subbannayya, T., Rajappa, M., Mohan, S. V., ... & Chatterjee, A. (2020). Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer. Gastric Cancer, 23(5), 796-810.

Artarini, A., Meyer, M., Shin, Y. J., Huber, K., Hilz, N., Bracher, F., ... & Karlas, A. (2019). Regulation of influenza A virus mRNA splicing by CLK1. Antiviral research, 168, 187-196.

Sun, L., Cheong, J. E., Zaffagni, M., Zhou, K., & Zetter, B. (2018). Discovery of novel water-soluble derivatives of mebendazole as selective CLK1/4 kinase inhibitors and their anticancer cancer activity.

Uzor, S., Zorzou, P., Bowler, E., Porazinski, S., Wilson, I., & Ladomery, M. (2018). Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention. Gene, 670, 46-54.

Sako, Y., Ninomiya, K., Okuno, Y., Toyomoto, M., Nishida, A., Koike, Y., ... & Hagiwara, M. (2017). Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Scientific reports, 7(1), 1-9.

Sun, Q. Z., Lin, G. F., Li, L. L., Jin, X. T., Huang, L. Y., Zhang, G., ... & Yang, S. Y. (2017). Discovery of potent and selective inhibitors of cdc2-like kinase 1 (clk1) as a new class of autophagy inducers. Journal of medicinal chemistry, 60(14), 6337-6352.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols